7) Reactivators of AChE as Therapeutics (ReACT)
Abstract
Exposure to nerve agents is at worst catastrophic and at best disabling for an extended period – and in most cases the onset of symptoms is very fast. Nerve agents work by blocking the signal flow across nerve junctions, ultimately resulting in a loss of ability to control both voluntary and involuntary muscles and death by asphyxiation. Currently, there is only one FDA- approved post-exposure drug treatment that restores the activity of the human molecule deactivated by nerve agent, and it is essentially unchanged since the 1950s. The ReACT portfolio is developing a number of different candidate medicines that are effective against a broader range of nerve agents – including fourth generation agents - than had ever before been thought possible. Successful development of these medicines will greatly enhance the ability of the Warfighter to survive and potentially stay in the fight and move forward.
Document Details
- Document Type
- Accomplishment
- Publication Date
- Oct 01, 2025
- Source ID
- dffcfe24783730f74b9d74a9bfc32aef